Publications by authors named "M Graupe"
Observed Versus Predicted Vaginal Birth After Cesarean for Patients of a Community Health Center.
J Midwifery Womens Health
September 2024
Introduction: The Maternal-Fetal Medicine Units Network calculator for vaginal birth after cesarean (VBAC) probability was updated to exclude a race and ethnicity variable, but its impact on marginalized groups is unknown. We assessed the tool with attention to birth history and body mass index (BMI) in a predominately Hispanic cohort and examined the possible effect of discouraging labor after cesarean (LAC) with a low score.
Methods: We conducted a retrospective cohort study of LACs by patients who entered spontaneous or induced labor with a live, nonanomalous fetus in cephalic presentation between 2012 and 2022.
Article Synopsis
- - Lenacapavir (LEN) is a long-acting injectable drug approved for treating HIV-1, notable for its dual atropisomeric form that maintains a stable ratio in the bloodstream despite rapid interconversion.
- - The drug shows low systemic clearance in humans and animals, with a primary elimination route through fecal excretion rather than urine, while its concentration remains stable in plasma.
- - The study reveals that LEN does not enter the brain due to its interaction with P-glycoprotein and emphasizes the significance of intestinal excretion (IE) for drugs that are metabolically stable and eliminated slowly.
Background And Objective: Lenacapavir (LEN) is a novel, first-in-class, multistage, selective inhibitor of human immunodeficiency virus type 1 (HIV-1) capsid function recently approved for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection. The purpose of this multicohort study was to evaluate the pharmacokinetics, metabolism, excretion, safety, and tolerability of LEN following a single intravenous (IV) infusion of 10 mg LEN or 20 mg [C]LEN in healthy participants.
Methods: Twenty-one healthy adult participants were enrolled into the study and received either a single IV dose of 10 mg LEN (n = 8 active, n = 3 placebo; cohort 1) or a single IV dose of 20 mg [C]LEN containing 200 µCi (n = 10; cohort 2).
Objective: Exhausted hepatitis B virus (HBV)-specific CD8 T cells in chronic HBV infection are broadly heterogeneous. Characterisation of their functional impairment may allow to distinguish patients with different capacity to control infection and reconstitute antiviral function.
Design: HBV dextramer+CD8 T cells were analysed ex vivo for coexpression of checkpoint/differentiation markers, transcription factors and cytokines in 35 patients with HLA-A2+chronic hepatitis B (CHB) and in 29 control HBsAg negative CHB patients who seroconverted after NUC treatment or spontaneously.
Background: The Pediatric Acute Care Cardiology Collaborative (PAC3) is a learning network focused on improving acute care cardiology patient outcomes. Data submission timeliness is a vulnerability for PAC3 and most clinical registries, directly affecting collaborative benchmarking, quality improvement (QI) and research projects.
Objective: PAC3 conducted a collaborative-wide QI project addressing data timeliness and efficiency.